BASEL, SWITZERLAND – Actelion Ltd (SIX: ATLN) announced that it has appointed André C. Muller (49) as the company’s Chief Financial Officer and member of Actelion’s Executive Committee (AEC). He succeeds Andrew J. Oakley (51), who will focus on opportunities outside Actelion. Mr. Muller will take office on 01 September 2013.
Jean-Paul Clozel, M.D. and Chief Executive Officer of Actelion, commented: “I am pleased to welcome André Muller as Chief Financial Officer at Actelion. He brings vast experience as a pharmaceutical finance executive and I am confident that André will make a significant contribution to Actelion’s continued success.”
André C. Muller is a French citizen joining Actelion from Pierre Fabre SA, an international pharmaceutical and cosmetic group, where he held various positions from 1994 until 2011, most recently as Chief Financial Officer. He holds an MBA from the Business School EM, Lyon
Thanking Andrew Oakley for his contribution, Jean-Paul Clozel said: “Over the last decade Andrew has led Actelion’s finance office, supporting our significant expansion. We wish him every success for his future.”
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion’s first drug Tracleer® (bosentan), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium – the single layer of cells separating every blood vessel from the blood stream. Actelion’s over 2,300 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®).
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.